Lupin Will Pay $150M To End Glumetza Antitrust Suit
Direct buyers of blood sugar medication Glumetza on Monday inked a $150 million deal in California federal court with Lupin Pharmaceuticals, which is accused of taking part in a scheme to...To view the full article, register now.
Already a subscriber? Click here to view full article